Haematologica, Vol 92, Issue 1, 27-34 doi:10.3324/haematol.10692
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lierman, E.
Right arrow Articles by Cools, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lierman, E.
Right arrow Articles by Cools, J.
Related Collections
Right arrowRelated Article

Myelod Malignancies

The ability of sorafenib to inhibit oncogenic PDGFRß and FLT3 mutants and overcome resistance to other small molecule inhibitors

Els Lierman, Idoya Lahortiga, Helen Van Miegroet, Nicole Mentens, Peter Marynen, Jan Cools

From the Department of Molecular and Developmental Genetics, Flanders Interuniversity Institute for Biotechnology (VIB), University of Leuven, Leuven, Belgium (EL, IL, HVM, NM, PM, JC); Division of Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain (IL)

Correspondence: Jan Cools, M.D., Department of Molecular and Developmental Genetics, Campus Gasthuisberg O&N1, Herestraat 49 (BOX 602), B-3000 Leuven, Belgium. E-mail: jan.cools{at}med.kuleuven.be

Background and Objectives: Activated tyrosine kinases are implicated in the pathogenesis of chronic and acute leukemia, and represent attractive targets for therapy. Sorafenib (BAY43-9006, Nexavar®) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families. We investigated the efficacy of sorafenib at inhibiting mutants of the receptor tyrosine kinases PDGFRß, KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies.

Design and Methods: We tested the effect of sorafenib on the proliferation of hematopoietic cells transformed by ETV6-PDGFRß, FLT3 with an internal tandem duplication or D835Y point mutation, and the KIT(D816V) mutant. The direct effect of sorafenib on the activity of these kinases and their downstream signaling was tested using phospho-specific antibodies.

Results: We show that sorafenib is a potent inhibitor of ETV6-PDGFRß and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors. Sorafenib induced a cell cycle block and apoptosis in the acute myeloid leukemia cell lines MV4-11 and MOLM-13, both expressing FLT3 with an internal tandem duplication, whereas no effect was observed on four other acute myeloid leukemia cell lines. The imatinib-resistant KIT(D816V) mutant, associated with systemic mastocytosis, was found to be resistant to sorafenib.

Interpretation and Conclusions: These results warrant further clinical studies of sorafenib for the treatment of myeloid malignancies expressing activated forms of PDGFRß and FLT3.

Key words: oncogene, tyrosine kinase, resistance.


Related Article

ETV6 and PDGFRB: a license to fuse
Els Lierman, Jan Cools
Haematologica 2007 92: 145-147. [Full Text] [PDF]



This article has been cited by other articles:


Home page
JCOHome page
R. C. Chen, M. S. Chin, A. K. Ng, Y. Feng, D. Neuberg, B. Silver, G. S. Pinkus, M. A. Stevenson, and P. M. Mauch
Early-Stage, Lymphocyte-Predominant Hodgkin's Lymphoma: Patient Outcomes From a Large, Single-Institution Series With Long Follow-Up
J. Clin. Oncol., January 1, 2010; 28(1): 136 - 141.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
M. A.E. van der Kaaij, N. Heutte, J. van Echten-Arends, J. M.M. Raemaekers, P. Carde, E. M. Noordijk, C. Ferme, J. Thomas, H. Eghbali, P. Brice, et al.
Sperm quality before treatment in patients with early stage Hodgkin's lymphoma enrolled in EORTC-GELA Lymphoma Group trials
Haematologica, December 1, 2009; 94(12): 1691 - 1697.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. von Bubnoff, R. A. Engh, E. Aberg, J. Sanger, C. Peschel, and J. Duyster
FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro
Cancer Res., April 1, 2009; 69(7): 3032 - 3041.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
M. Porcu, O. Gielen, J. Cools, and K. De Keersmaecker
JAK1 mutation analysis in T-cell acute lymphoblastic leukemia cell lines
Haematologica, March 1, 2009; 94(3): 435 - 437.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. Jilaveanu, C. Zito, S. J. Lee, K. L. Nathanson, R. L. Camp, D. L. Rimm, K. T. Flaherty, and H. M. Kluger
Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib
Clin. Cancer Res., February 1, 2009; 15(3): 1076 - 1085.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Moreno-Aspitia, R. F. Morton, D. W. Hillman, W. L. Lingle, K. M. Rowland Jr, M. Wiesenfeld, P. J. Flynn, T. R. Fitch, and E. A. Perez
Phase II Trial of Sorafenib in Patients With Metastatic Breast Cancer Previously Exposed to Anthracyclines or Taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336
J. Clin. Oncol., January 1, 2009; 27(1): 11 - 15.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J. M. Llovet, and M. Lynch
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
Mol. Cancer Ther., October 1, 2008; 7(10): 3129 - 3140.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. Dewaele, B. Wasag, J. Cools, R. Sciot, H. Prenen, P. Vandenberghe, A. Wozniak, P. Schoffski, P. Marynen, and M. Debiec-Rychter
Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor-Associated PDGFRAD842V Mutation
Clin. Cancer Res., September 15, 2008; 14(18): 5749 - 5758.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
W. Zhang, M. Konopleva, Y.-x. Shi, T. McQueen, D. Harris, X. Ling, Z. Estrov, A. Quintas-Cardama, D. Small, J. Cortes, et al.
Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia
J Natl Cancer Inst, February 6, 2008; 100(3): 184 - 198.
[Abstract] [Full Text] [PDF]


Home page
CA Cancer J ClinHome page
R. D. Loberg, D. A. Bradley, S. A. Tomlins, A. M. Chinnaiyan, and K. J. Pienta
The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy
CA Cancer J Clin, July 1, 2007; 57(4): 225 - 241.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
E. Lierman and J. Cools
ETV6 and PDGFRB: a license to fuse
Haematologica, February 1, 2007; 92(2): 145 - 147.
[Full Text] [PDF]